A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2022-02-18
Adverse events
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-06-22 (study day 111); relationship: N
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-23 (study day 204); relationship: not assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-02-04 (study day 703); relationship: not assessed
Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-05-14 (study day 803); relationship: N
Grade 1 Nausea — outcome: UNKNOWN; onset 2024-08-09 (study day 890); relationship: not assessed
Data queries
No data queries.